Reporter brief
Rapamycin tested in RCT of elderly adults for immune, cognitive, and functional effects.
What happened
This was a translational RCT investigating whether rapamycin, an FDA-approved immunosuppressant, could improve immune responsiveness, cognition, and functional outcomes in elderly adults aged 70-95. The abstract describes the trial design and rationale based on preclinical findings in mice but does not report results, sample size, or effect sizes from the human trial.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Elderly persons aged 70-95
- Design
- Rct
- Sample
- —
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Dec 4, 2018
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.